This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Beatrice Noce, Sara Marchese, Marta Massari, Chiara Lambona, Joana Reis, Francesco Fiorentino, Alessia Raucci, Rossella Fioravanti, Mariana Castela, Alessandro Mormino, Stefano Garofalo, Cristina Limatola, Lorenzo Basile, Andrea Gottinger, Claudia Binda, Andrea Mattevi, Antonello Mai, and Sergio Valente Journal of Medicinal Chemistry 2025 DOI: 10.1021/acs.jmedchem.4c02644 NADPH oxidases (NOXs) are enzymes dedicated to reactive oxygen species (ROS) production and are implicated in cancer, neuroin
SATURDAY, March 8, 2025 -- Cardiovascular disease is a general term that refers to many different types of heart problems.Heart disease is the No. 1 cause of death in the United States. In fact, one American dies from heart disease every 33.
1S. M. Rowe, A. Price, D. J. Murphy, J. Lin, E. N. Nartey, A. Chaikuad, K. Wong, J. E. Cottom, N. O. Concha, R. A. Reid, E. R. Dickinson, M. Jundt, K. Kammerer, M. Steidel, T. Mathieson, T. Werner, E. K. Grant, C. K. Stanborough, M. Rouah, J. Wojno-Picon, P. Pogny, J. Pettinger, D. J. Norman, H. Wilders, F. Rianjongdee, G. Valdes-Garcia, N. Nevins, R.
Notable imbalances exist across STEM subjects at the undergraduate level, with many female students enrolling in fields like psychology and subjects allied to medicine (eg, nursing), which often lead to lower-paid career paths. However, women remain dramatically underrepresented in core STEM fields, accounting for just 34 percent of the STEM workforce and being vastly outnumbered by men in most STEM majors.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
The global business landscape is complex, and responsible design has emerged as a critical imperative for organizations across sectors. It represents a fundamental shift from viewing design merely as a creative output to recognizing it as an ethical responsibility embedded within institutional structures and processes. True transformation toward responsible design practices cannot be achieved through superficial initiatives or isolated projects.
Dr Lopa Bakrania brings over 18 years of experience in pharmaceutical process chemistry and CMC regulatory affairs. As Executive Director of CMC Regulatory Affairs at Biohaven , she leads efforts to develop innovative therapies from the clinic to market approval. Throughout her career, Bakrania has held pivotal roles at renowned companies, including Biohaven, where she contributed to the development of therapies, such as migraine treatment Nurtec ODT.
Dr Lopa Bakrania brings over 18 years of experience in pharmaceutical process chemistry and CMC regulatory affairs. As Executive Director of CMC Regulatory Affairs at Biohaven , she leads efforts to develop innovative therapies from the clinic to market approval. Throughout her career, Bakrania has held pivotal roles at renowned companies, including Biohaven, where she contributed to the development of therapies, such as migraine treatment Nurtec ODT.
The month of March offers so many opportunities to celebrate the contributions women have made across different fields all over the world. As we continue to recognize women this month, were excited to bring the celebration to Adobe Summit 2025! Our Women in Digital Breakfast is returning for its ninth year and we’re also supporting the nonprofit organization Girls Who Code.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
130 
Let's personalize your content